Soucie J M, Symons J, Evatt B, Brettler D, Huszti H, Linden J
Hematologic Diseases Branch, Division of AIDS, STD, and TB Laboratory Research, National Center for Infectious Diseases, Centers for Disease Control and Prevention, Atlanta, GA 30333, USA.
Haemophilia. 2001 Mar;7(2):198-206. doi: 10.1046/j.1365-2516.2001.00484.x.
Information from the medical records of 2650 US males with haemophilia living in six states was used to examine the influence of infusing factor concentrate at home (home therapy) and other variables on rates of hospitalization for a haemorrhagic bleeding complication (HBC) over a 4-year period. Bleeding complications included actual and suspected haemorrhagic events but excluded elective admissions for procedures necessitated by haemorrhage (e.g. joint synovectomy). Other risk determinants considered in the analyses included age, race, employment status, health insurance type, care received in federally funded haemophilia treatment centres (HTCs), factor deficiency type and severity, amount of factor prescribed, prophylactic treatment, and presence of inhibitors at baseline. Survival analysis methods were used to evaluate relationships between baseline risk factors and subsequent hospitalization rates. During 8708 person years (PYs) of follow-up, 808 subjects (30.5%) had a total of 1847 bleeding-related hospitalizations; an overall rate of 21.2 admissions per 100 PYs. Using proportional hazards regression to adjust for all of the studied factors, we found that home therapy use (among residents of four of the states) and care in HTCs were independently associated with a decreased risk for a first HBC. Patients who had government-sponsored health insurance or who had no insurance, those of minority race or ethnicity, those with higher levels of factor use, and those with inhibitors were at increased HBC risk. We conclude that the use of home therapy and receipt of care in HTCs are each associated with a substantially lower risk for HBC among males with haemophilia.
利用居住在六个州的2650名美国男性血友病患者的病历信息,研究了在家输注凝血因子浓缩物(家庭治疗)及其他变量对4年期间出血性出血并发症(HBC)住院率的影响。出血并发症包括实际和疑似出血事件,但不包括因出血而进行的择期手术入院(如关节滑膜切除术)。分析中考虑的其他风险决定因素包括年龄、种族、就业状况、医疗保险类型、在联邦资助的血友病治疗中心(HTC)接受的治疗、凝血因子缺乏类型和严重程度、凝血因子处方量、预防性治疗以及基线时是否存在抑制剂。采用生存分析方法评估基线风险因素与随后住院率之间的关系。在8708人年的随访期间,808名受试者(30.5%)共发生1847次与出血相关的住院;每100人年的总体住院率为21.2次。使用比例风险回归对所有研究因素进行调整后,我们发现家庭治疗的使用(四个州的居民中)和在HTC接受治疗与首次发生HBC的风险降低独立相关。拥有政府资助医疗保险或没有保险的患者、少数种族或族裔患者、凝血因子使用量较高的患者以及有抑制剂的患者发生HBC的风险增加。我们得出结论,家庭治疗的使用和在HTC接受治疗均与血友病男性发生HBC的风险大幅降低相关。